YHLO

Name

YHLO

Legal name

Shenzhen YHLO Biotech Co., Ltd.

Website

https://en.szyhlo.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

In-Vitro Diagnostics (IVD) Instruments and Reagents

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Clinical Chemistry & Immunoassay Systems (HLAHAAAA)

akta.pro secondary industries

Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI)

Keywords

• In-vitro diagnostics
• Chemiluminescence immunoassay
• Clinical chemistry analyzers
• Autoimmune disease diagnostics
• Laboratory automation systems

Headquarters

HQ city

Shenzhen

HQ country

China

HQ region

Asia

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. IVD Instruments and Analyzers: Sale of automated CLIA analyzers (iFlash 1200/1800/3000/9000), biochemistry analyzers (iBC 900), and total laboratory automation systems (iTLA mini Plus, iTLA Max). Instruments are sold directly and through distributors to hospitals, labs, and healthcare providers.
2. IVD Reagents and Test Kits: Sale of reagent consumables for CLIA, biochemistry, immunoblotting, and other platforms covering autoimmune, reproductive health, infection, liver disease, diabetes, cardiac markers, tumor markers, and more. Over 300 products generate recurring reagent revenue.
3. Professional Services and Technical Support: Technical support, training, and service center operations at seven overseas locations, providing installation, maintenance, and application support to global customers.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels10 records

Core offering

YHLO develops, manufactures, and distributes in-vitro diagnostic (IVD) instruments and reagents across six technology platforms: chemiluminescence immunoassay (CLIA), biochemistry, indirect immunofluorescence, immunoblotting, fluorescent immunochromatography, and colloidal gold immunochromatography. Its core instrument family includes the iFlash CLIA analyzers (iFlash 1200/1800/3000/9000), biochemistry analyzers (iBC 900), total laboratory automation systems (iTLA mini Plus, iTLA Max), and ESR analyzers. The reagent portfolio covers over 300 products for autoimmune disease, reproductive health, infection, liver disease, diabetes, cardiac markers, and tumor markers.

Product overview

YHLO is an in vitro diagnostic (IVD) company specializing in developing, manufacturing, and distributing diagnostic instruments and reagents. The core product portfolio centers on the iFlash family of chemiluminescence immunoassay (CLIA) analyzers: iFlash 9000 (high-throughput, 600 tests/hour), iFlash 3000 (300 tests/hour), iFlash 1800 (bench-top, 180 tests/hour), and iFlash 1200 (compact, 120 tests/hour). These analyzers run CLIA Test Panels covering reproductive health, autoimmunity, diabetes, infectious diseases, and routine parameters. YHLO complements the CLIA platform with laboratory automation solutions including iTLA mini Plus (compact automation with AI/machine vision) and iTLA Max (high-capacity, 1,200 samples/hour), plus iModules for modular integration. The biochemistry line includes iBC 900 analyzer. The subsidiary Drawray brand offers microfluidic products (iStar 500). Supporting platforms include Tenfly Phoenix (immunoblot), iMega Flow (flow cytometry), Vision ESR Analyzer, and Unicell (immunofluorescence). YHLO's technology bases span six platforms: chemiluminescence, biochemistry, indirect immunofluorescence, immunoblotting, fluorescent immunochromatography, and colloidal gold immunochromatography. The company also offers specialized assays like the sCD146 CLIA assay (CNS diagnostics) and the PIFI Digital Intelligence Platform for islet function assessment. The portfolio addresses diagnostics across autoimmunity, reproductive health, infection, liver disease, diabetes, cardiovascular diseases, and respiratory diseases.

Differentiator

Problem solved

Functional benefit

Brands

• Drawray: Subsidiary brand producing microfluidics products including iStar 500 (highly-automated Mono-test Analyzer) and Unicell (Immunofluorescence Reader)
• iTLA
• iFlash
• Tenfly
• iMega Flow
• Vision

Products and services

• iFlash 9000 Chemiluminescence Immunoassay Analyzer High-throughput CLIA analyzer delivering up to 600 tests/hour for demanding laboratory environments, with 2 optional sample loading units, expandable to 4 units linked with iTLA system, 40 reagent positions with onboard refrigeration, and 3000 reaction vessel capacity.
• iFlash 3000 Chemiluminescence Immunoassay Analyzer Fully automatic CLIA analyzer with 300 tests/hour throughput for middle and large laboratories, scalable up to 4 units and seamlessly integrable with TLA systems.
• iFlash 1800 Chemiluminescence Immunoassay Analyzer Bench-top CLIA analyzer for clinical labs with up to 180 tests/hour throughput, 20 onboard reagent positions, and 50 sample positions with emergency function.
• iFlash 1200 Chemiluminescence Immunoassay Analyzer Compact CLIA workstation for low-mid volume testing laboratories with up to 120 tests/hour, 16 sample positions, 15 reagent positions, and up to 500 reaction vessels onboard.
• iTLA mini Plus Laboratory Automation System Compact total laboratory automation system integrating input, output and centrifuge modules, processing up to 600 tubes/hour per module, supporting multiple sample loading methods with AI and machine vision for intelligent sample management, connecting up to 4 biochemistry or immunology analyzers.
• iTLA Max Intelligent Total Laboratory Automation System High-capacity intelligent total laboratory automation system processing up to 1,200 samples/hour with balanced speed, integrating AI and visual recognition for comprehensive laboratory workflow automation.
• iBC 900 Fully Automatic Chemistry Analyzer High-speed fully automatic biochemistry analyzer produced at YHLO's Xiangtan manufacturing center as part of the expanded diagnostic portfolio.
• CLIA Test Panel Comprehensive test panels including reproductive health, autoimmunity, diabetes, infectious diseases and routine parameters delivered on the iFlash chemiluminescence platform.
• sCD146 CLIA Assay World's first sCD146 test for cerebrospinal fluid, approved by Guangdong Medical Products Administration, demonstrating AUC of 0.9962 for detecting blood-brain barrier damage in CNS demyelinating disease diagnostics.
• PIFI Digital Intelligence Platform Standardized Pancreatic Islet Function Index (PIFI) digital intelligence platform using big data-driven intelligent computing for islet function assessment, based on clinical data from over 10,000 Chinese cases.
• GLINE-2019-nCoV Ag COVID-19 Rapid Antigen Test Kit Colloidal gold immunoassay for rapid qualitative determination of nucleocapsid protein of SARS-CoV-2 in nasal or nasopharyngeal swab, delivering results in 15 minutes without electronic equipment; CE marked and BfArM approved.
• Vision ESR Analyzer Erythrocyte Sedimentation Rate (ESR) analyzer from YHLO's product portfolio.
• Tenfly Phoenix Immunoblot System Immunoblot system for autoimmune disease diagnostics within YHLO's Tenfly product line.
• iMega Flow Flow cytometry-based diagnostic platform for liquid chip testing from YHLO's technology portfolio.

Quantifiable outcome

• iTLA mini Plus processes up to 600 tubes/hour per module, enabling efficient multi-source, multi-batch sample processing
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability7 records

Feature11 records

Partnerships

14 partnerships are on record, tiered flagship, minor and core.

• SanofiflagshipStrategic or Co-development Partner · 6 November 2025At the 8th China International Import Expo (CIIE), YHLO and Sanofi launched the China Type 1 Diabetes Ecosystem Co-construction Alliance. YHLO contributes its diagnostic portfolio — including Adiponectin (early T2D risk prediction), autoantibody panel (GADA, IAA, IA-2A, ICA, ZnT8A for T1D detection), C-peptide and Insulin (β-cell function evaluation), and the PIFI digital intelligence platform — to enable early screening, accurate classification, and precise intervention for Type 1 diabetes. Sanofi contributes Tzield (teplizumab), the world's first therapy proven to delay T1D onset. This partnership integrates diagnosis with therapy for diabetes care.
• C-Mer Eye Care Holdings LimitedminorOthers · 16 February 2022Shenzhen YHLO and C-Mer jointly donated 300,000 COVID-19 Rapid Antigen Tests to Hong Kong (February 16, 2022), subsequently increased to 600,000 tests (February 22, 2022). Tests were distributed through charities to high-risk populations including elderly care workers, cleaning and security staff, and bus drivers.
• Peking UniversitycoreStrategic or Co-development PartnerYHLO and Peking University established a Joint Laboratory for Molecular Diagnostics of Infectious Diseases. The collaboration focuses on R&D in liver disease diagnostics and infectious disease molecular diagnostics. The joint lab has produced multiple high-impact publications, including a study on inactivated COVID-19 vaccine booster efficacy against the Omicron variant published in Journal of Infection (IF 38.637). The partnership leverages Peking University's academic talent and YHLO's technology and commercialization capabilities.
• Institute of Biophysics, Chinese Academy of SciencescoreStrategic or Co-development PartnerYHLO has established collaborative laboratories with the Institute of Biophysics of the Chinese Academy of Sciences as part of its industry-academia-research integration strategy.
• Chinese University of Hong Kong (Shenzhen)coreStrategic or Co-development PartnerYHLO has established collaborative laboratories with the Chinese University of Hong Kong (Shenzhen) for joint research in IVD technology and diagnostics.
• Southern University of Science and TechnologycoreStrategic or Co-development PartnerYHLO collaborates with Southern University of Science and Technology on joint research and development in the IVD field as part of its academic partnership network.
• Third People's Hospital of ShenzhencoreStrategic or Co-development PartnerYHLO maintains a collaborative laboratory with Third People's Hospital of Shenzhen for clinical research and diagnostic development.
• Huazhong University of Science and TechnologycoreStrategic or Co-development PartnerYHLO has an academic collaboration with Huazhong University of Science and Technology for joint research in medical diagnostics.
• National Innovation Center for High-Performance Medical DevicescoreStrategic or Co-development PartnerYHLO partners with the National Innovation Center for High-Performance Medical Devices as part of China's high-performance medical device innovation ecosystem.
• Prof. Yanxi Yun (Academician)coreStrategic or Co-development PartnerThe world's first sCD146 CLIA assay was developed jointly with Prof. Yanxi Yun, an academician, representing a breakthrough in precision diagnosis of CNS demyelinating diseases. The collaboration strengthens China's leadership in this diagnostic field.
• MBL (Medical & Biological Laboratories Co., Ltd.)coreChannel Partner/ Reseller/ DistributorMBL serves as YHLO's Japanese marketing authorization holder. YHLO's COVID-19 Rapid Antigen Test Kit was authorized by Japanese PMDA and supplied through MBL. MBL is a long-term strategic partner that has assisted in organizing YHLO Japan R&D Center events.
• JSR CorporationminorOthersJSR Corporation is listed as a representative partner from the Japanese side at the YHLO Japan R&D Center opening ceremony.
• Beckman CoultercoreTechnology or IntegrationYHLO's iModules (later iTLA) modular automation system has been integrated with Beckman Coulter's Power Express clinical lab automation system. A joint installation was completed at the Sixth Hospital of Wuhan, creating a Total Laboratory Automation (TLA) solution that boosts daily workload efficiency. This cross-platform integration demonstrates YHLO's open automation architecture.
• BSI (British Standards Institution)coreOthersBSI is YHLO's primary EU Notified Body for IVDR CE certification. YHLO has received IVDR CE certification for 200 products from BSI, including the first full Blood Bank Panel certification for a Chinese IVD company. BSI's Dr. Michael Weissig visited YHLO to present IVDR certificates. BSI is the world's first national standards institution and founding member of ISO.

Scale indicators12 records

Recent moves13 records

Expansion highlights5 records

Direct peers

• Tosoh Bioscience: Japanese IVD manufacturer offering the AIA-CL AIA-900/1800 chemiluminescence immunoassay analyzers. Comparable vertically-integrated CLIA model with established presence in Asian markets and a meaningful reagent menu overlap with iFlash.
• Mindray (Shenzhen Mindray Bio-Medical Electronics): Largest Chinese IVD and medical device company with a comprehensive CLIA platform (CL-series) plus BC series clinical chemistry analyzers competing directly with iFlash and iBC 900. Both share Shenzhen origin, Chinese class A hospital installed base, and global expansion via distributors into 115+ countries.
• Autobio Diagnostics: Chinese IVD manufacturer offering the AutoLumo/A2000/A6200 CLIA analyzers and matching reagent menu. Competes with YHLO across mid-tier immunoassay panels in Chinese hospitals and in emerging international markets, particularly in autoimmune and infectious disease testing.
• Maccura Biotechnology: Chinese IVD manufacturer with chemiluminescence and clinical chemistry platforms (e.g., Lumiray series) and a broad reagent menu focused on infectious disease, reproductive health, and autoimmune testing. Direct overlap with YHLO's iFlash family and reagent catalog.
• DiaSorin: Italian IVD specialist with the LIAISON XL chemiluminescence immunoassay platform and a strong specialty/specialized assay portfolio (infectious disease, autoimmune, Vitamin D). Directly comparable to YHLO in CLIA architecture and reagent specialization strategy.
• Snibe (Shenzhen New Industries Biomedical Engineering): Shenzhen-headquartered Chinese IVD company whose MAGLUMI chemiluminescence immunoassay platform is the most direct iFlash competitor globally. Both companies compete head-to-head in CLIA analyzers and reagents across autoimmune, reproductive, infectious disease, and tumor markers, and both pursue international expansion through distributors.

Broad incumbents

• Siemens Healthineers: Operator of the Atellica IM immunoassay and ADVIA Centaur platforms with an extensive installed base of TLA-ready analyzers. Direct competitive benchmark in Chinese class A hospitals and across YHLO's growing international footprint.
• Beckman Coulter Diagnostics: Provider of the DxI/Access immunoassay family and Power Express total lab automation system — the latter is integrated with YHLO's iTLA at the Sixth Hospital of Wuhan. A partner and competitor at the same time, representing both collaboration (TLA integration) and competitive pressure (own install base).
• Roche Diagnostics: Global IVD market leader with cobas e801/e601 immunoassay systems, Elecsys reagent menu, and proprietary Total Laboratory Automation (cobas connection modules). Sets the benchmark YHLO competes against on throughput, assay breadth, and lab-automation footprint in hospitals worldwide.
• Abbott Diagnostics: Global IVD incumbent offering the Alinity ci-series immunoassay/clinical chemistry analyzers and ARCHITECT i-series. Competes with iFlash/iBC 900 globally in hospital core labs and is the dominant vendor in many countries YHLO is targeting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCtvGAd6b7wIQE3Rkc-t5ycg
• Facebookfacebook.com/YHLObiotech
• LinkedInlinkedin.com/company/yhlo
• Instagraminstagram.com/yhlobiotech/?next=%2F
• Xx.com/yhlobiotech

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about YHLO